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ADAM19, an enzyme from the ADAM (a disintegrin and
metalloproteinase) family, is involved in various cell–cell and
cell–matrix interactions. It can cleave epidermal growth factor
(EGF)-like growth factors, such as heparin-binding
(HB)-EGF and neuregulin (NRG), from the cell membrane.
ADAM-mediated EGF receptor activation is crucial in the
development of renal pathology. Based on these data, we
studied ADAM19 in human nephrogenesis and renal disease.
We collected 20 fetal kidneys and 56 biopsies from patients
with various renal diseases. The unaffected part of kidneys
from eight patients with renal cell carcinoma served as
control. RNA in situ hybridization revealed widespread
ADAM19 mRNA expression in the nephrogenic zone of
human fetal kidneys. Normal human kidneys showed
constitutive ADAM19 expression in distal tubules and
endothelial cells, whereas proximal tubules were negative.
In renal disease, ADAM19 was de novo expressed in proximal
tubules and glomerular mesangium and upregulated in distal
tubules and endothelial cells. ADAM19 colocalized with
tubular and interstitial NRG, however, not with HB-EGF.
Independent of renal disorder, mesangial ADAM19
expression was associated with glomerular damage as
assessed by mesangial matrix expansion, focal
glomerulosclerosis, and glomerular macrophage influx (all
Po0.001). ADAM19 in proximal tubules and in peritubular
capillaries was associated with interstitial fibrosis (Po0.05).
Finally, increasing tubular ADAM19 was associated with
declining renal function (Po0.05). The abundant ADAM19
expression during nephrogenesis points to a role in growth
promotion and regulation. The high ADAM19 expression in
renal disease suggests involvement in profibrotic and
proinflammatory processes leading to renal deterioration.
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ADAM (a disintegrin and metalloproteinase) proteins, also
known as adamalysins, are a family of type-1 transmembrane
glycoproteins. ADAMs contain all or some of the following
domain structures: a signal peptide, a prodomain, a
metalloproteinase domain, a disintegrin domain, a cysteine-
rich domain, an epidermal growth factor (EGF)-like domain,
a transmembrane region, and a cytoplasmic tail.1–4 ADAMs
are crucially involved in the proteolytic cleavage of
extracellular domains of transmembrane proteins, such as
cytokines, growth factors, receptors, and cell adhesion
molecules.5 Besides this process of protein ectodomain
shedding, ADAMs are engaged in cell–cell fusion, adhesion,
and intracellular signaling.3,6 These functions of ADAMs are
illustrated by their involvement in various biological
processes, like sperm–egg binding and fusion,7 trophoblast
invasion and degradation of extracellular matrix during
pregnancy,8 angiogenesis, and neovascularization.9
Family member ADAM19 (also known as Meltrin b) is
catalytically active, as demonstrated by the proteolytic
activity of purified recombinantly expressed soluble forms
of ADAM19.10 ADAM19 cleaves heparin-binding EGF (HB-
EGF) and neuregulin (NRG), both members of the EGF
family.11,18 EGF proteins are crucial in diabetes-related
kidney growth.12 Furthermore, ADAM-mediated activation
of the EGF receptor through shedding of EGF family
members is crucial in the development of renal pathology.13
ADAM19 knockout mice develop severe cardiac abnormali-
ties. Kidneys of these knockout mice, however, had a normal
morphological appearance. Based on the cardiac defects,
most animals died shortly after birth.14,15 There is still debate
on whether and to what extent these cardiovascular
abnormalities are related to aberrant shedding of EGF
receptor ligands by ADAM19.11,14,15 Next to this role in
development, ADAM19 is suggested to play a role in
inflammation through extravasation of monocytes.16
In renal cell carcinoma, ADAM19 mRNA is upregulated in
samples of cancerous tissue when compared to the non-
cancerous tissue of the same kidney.17 However, no data on
ADAM19 localization in human kidneys exist. As it has been
suggested that ADAM19 is involved in growth- and
development-related processes, we studied ADAM19 in
human nephrogenesis, normal kidneys, various native renal
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diseases, and renal transplantation. The extent of ADAM19
expression was related to renal structural and functional
deterioration as measured by glomerular and interstitial
damage and serum creatinine.
RESULTS
Patient characteristics
Patient characteristics are presented in Table 1. Controls
differed in age and blood pressure from some of the disease
groups. All disease groups had significantly higher serum
creatinine levels than controls, except for minimal change
disease. Patients with minimal change nephropathy, mem-
branoproliferative glomerulonephritis (MPGN), membra-
nous glomerulopathy, diabetic nephropathy, and focal
glomerular sclerosis had significantly higher levels of
proteinuria when compared with controls. Half of the
patients with the studied diseases received antihypertensive
and/or antiproteinuric pharmacological treatment at the time
of the biopsy. All patients with acute allograft rejection
received immunosuppressive treatment.
Renal structural changes
Renal damage parameters, as indicators of renal structural
changes, are presented in Table 2. Glomerular damage
parameters mesangial matrix expansion (MME) and focal
glomerulosclerosis (FGS) were abundant in all diseases,
except for minimal change disease and acute allograft
rejection. Prominent glomerular macrophage influx was
observed in all diseases, except for minimal change disease,
hypertensive nephropathy, and membranous glomerulopa-
thy. Interstitial fibrosis was found in all diseases, except for
minimal change disease.
ADAM19 in nephrogenesis
In fetal kidneys, very strong ADAM19 mRNA expression was
noted in the nephrogenic zone. Epithelial cells of metaneph-
ric vesicles and S- and comma-shaped bodies, which are
derived from metanephric blastema, revealed very strong
ADAM19 mRNA expression (Figure 1a and b). To support
our finding of blastemal ADAM19 expression, we studied
tissue from a patient with nephroblastomatosis. Strong
ADAM19 mRNA expression was observed in the expanded
blastemal area (data not shown). The ureteric bud and its
developing collecting tubules showed very strong ADAM19
mRNA staining (Figure 1a, b, and e), as did the developing
tubular epithelial cells (Figure 1c). Strong ADAM19 mRNA
staining was observed in endothelial cells, mesangium,
visceral, and parietal epithelium of developing glomeruli
(Figure 1c). Strong ADAM19 mRNA expression was also seen
in endothelial cells of renal arteries and vessels, whereas
Table 1 | Patient characteristics
Diagnosis M/F (N) Age (year) SBP (mmHg) DBP (mmHg) Serum creatinine (mg/l) Proteinuria (g/day)
Control 4/4 68 (54–69) 112 (105–120) 70 (65–75) 85 (61–105) 0.8 (0.0–2.3)
Acute allograft rejection 4/2 45 (34–59)** 135 (110–160) 80 (60–110) 647 (198–1155)** 0.7 (0.2–7.2)
Minimal change disease 4/2 28 (8–66)** 133 (107–160) 80 (55–105) 87 (39–124) 4.2 (0.0–8.9)*
Membranous glomerulopathy 5/0 54 (33–68) 137 (100–178) 78 (50–82) 126 (99–350)** 13.8 (7.9–24.4)*
Wegener’s granulomatosis 3/2 70 (6–81) 114 (105–140) 76 (60–80) 231 (74–389)* 0.5 (0.3–3.2)
Hypertensive nephropathy 3/3 53 (25–73) 153 (130–250)* 83 (80–150)* 229 (134–570)** 0.9 (0.2–6.3)
Membranoproliferative glomerulonephritis 0/3 34 (31–37)* 130 (120–140) 85 (74–90) 710 (105–953)** 9.8 (8.2–11.5)*
Diabetic nephropathy 3/3 56 (41–66) 170 (120–180)* 90 (50–105) 117 (92–276)* 5 (3.0–6.0)*
FGS 5/3 58 (18–80) 155 (115–200)* 85 (60–150) 186 (114–896)** 6.4 (2.7–10.9)*
Systemic lupus erythematosus 1/4 38 (28–55)** 150 (110–250) 80 (70–110) 143 (97–267)** 2.8 (0.5–3.7)
IgA nephropathy 5/1 44 (23–59)** 130 (110–142) 84 (80–90)* 135 (87–200)** 2.4 (1.0–6.3)
DBP, diastolic blood pressure; FGS, focal glomerular sclerosis; IgA, immunoglobulin A; M/F, male-to-female ratio; SBP, systolic blood pressure.
Values are expressed as median and range.
*Po0.05 versus control; **Po0.01 versus control.
Table 2 | Renal structural changes
Diagnosis N MME Focal glomerulo-sclerosis Glomerular macrophages Interstitial fibrosis
Control 8 0.1 (0.0–0.2) 0 (0.0–0.2) 0.4 (0.3–0.7) 0 (0–1)
Acute allograft rejection 6 0.6 (0.2–1.6) 0 (0.0–1.4) 3.1 (1.0–8.7) 2.5 (1–4)
Minimal change disease 6 0.7 (0.0–2.5) 0 (0.0–1.2) 0.6 (0.2–2.9) 0 (0–0)
Membranous glomerulopathy 5 2.6 (1.2–3.2) 1.6 (0.4–3.0) 0.9 (0.0–9.0) 2 (2–3)
Wegener’s granulomatosis 5 1.5 (0.2–2.7) 0.4 (0.0–2.7) 3.5 (1.6–12.8) 1 (0–4)
Hypertensive nephropathy 6 2.4 (1.4–3.3) 1.6 (0.4–3.0) 0.5 (0.1–3.5) 3 (2–4)
Membranoproliferative glomerulonephritis 3 2 (2.0–2.2) 1 (1.0–1.5) 9.5 (4.1–15.0) 2 (2–3)
Diabetic nephropathy 6 3.6 (1.9–4.0) 1.6 (0.3–1.8) 2.3 (1.1–4.0) 2 (1–4)
FGS 8 2.9 (2.1–3.3) 2.5 (0.2–3.0) 1.4 (0.0–4.7) 2.5 (1–4)
Systemic lupus erythematosus 5 2.3 (1.5–2.8) 1.7 (0.0–2.3) 5.1 (1.7–6.7) 2 (1–4)
IgA nephropathy 6 2.4 (0.3–3.1) 1.0 (0.1–2.0) 2.8 (1.2–8.5) 1.5 (1–2)
FGS, focal glomerular sclerosis; IgA, immunoglobulin A; MME, mesangial matrix expansion.
Values are expressed as median and range.
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smooth muscle cells were moderately positive (Figure 1d).
These findings were consistent for all gestational ages (12–41
weeks) examined. ADAM19 mRNA was strongly expressed in
epithelial cells lining the large, irregular cysts in multicystic
renal dysplasia. In the intervening stroma, spindle cells (most
likely fibroblasts) and epithelial cells of an occasionally
present tubule showed strong ADAM19 expression as well
(Figure 1g). After birth (7 and 18 months), strong ADAM19
mRNA expression was found in vascular endothelial cells,
moderate ADAM19 expression in distal tubular cells, and
smooth muscle cells of renal arteries and vessels, whereas
weak expression was noted in the glomerular mesangium,
parietal epithelium, and endothelium.
ADAM19 in normal human kidneys
Scoring for ADAM19 staining intensity in normal kidneys
(Tables 3 and 4) showed moderate ADAM19 mRNA
expression in distal tubular cells (Figure 2a and b). Proximal
tubular cells, however, revealed no ADAM19 expression
(Table 3, Figure 2b). Moderate ADAM19 expression was also
found in glomerular visceral epithelial cells (Figure 2b) and
vascular smooth muscle cells (Figure 2c), whereas weak
ADAM19 mRNA expression was detected in the vascular
(Figure 2c) and glomerular endothelium.
ADAM19 in renal disease
The scoring for ADAM19 staining intensity in diseased
kidneys is shown in Tables 3 and 4. In contrast to normal
human kidneys, we found massive distal tubular ADAM19
mRNA expression in all disease states (Table 4, Figure 2e).
Proximal tubules showed no ADAM19 expression in controls
and revealed de novo ADAM19 expression in all renal diseases
(Table 3, Figure 2f). This was most prominent in MPGN.
Furthermore, peritubular capillaries were almost completely
negative for ADAM19 in controls, but markedly enhanced
staining was observed in all renal diseases (Table 4). In
glomeruli, we noted enhanced staining for ADAM19 in
glomerular visceral and parietal epithelium from especially
minimal change disease and diabetic nephropathy patients
(Tables 3 and 4, Figure 2f). In general, glomerular endothelial
ADAM19 was increased in all diseases, although mesangial
ADAM19, being virtually absent in controls, was de novo
expressed in all diseases. However, great variation in the
extent of ADAM19 expression was observed between groups
(Table 4). Vascular endothelial and smooth muscle cells,
which showed baseline expression of ADAM19 in controls,
revealed increased, although variable staining in all diseases
(Table 4, Figure 2g).
ADAM19 immunofluorescence stainings
Based on the massive tubular ADAM19 mRNA expression as
identified by in situ hybridization, we further analyzed the
tubular epithelial expression of ADAM19 using immuno-
fluorescence. ADAM19 protein was found throughout the
entire tubular epithelial cytoplasm, including the basolateral
side and, albeit to a lesser degree, the luminal side (Figure 3a
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Figure 1 | ADAM19 mRNA expression in human nephrogenesis.
All photographs are from fetal kidneys with a gestational age of 13
weeks, serving as representative images for all gestational ages
studied (week 12–41). Original magnification  200, unless stated
otherwise. (a) In the nephrogenic zone of fetal kidneys, ADAM19
mRNA was strongly expressed in the nephrogenic blastema (arrows)
(original magnification  100). (b) In a higher magnification of the
same fetal kidney, massive ADAM19 mRNA expression was observed
in the ureteric bud (arrows), nephrogenic vesicles (arrowheads), and
comma-shaped bodies (open arrows). (c) In a developing glomerulus,
intensive ADAM19 staining was observed in the parietal (open
arrows) and visceral (arrowheads) epithelium (original magnification
 400). Also, developing tubular structures expressed ADAM19
abundantly (arrows). (d) ADAM19 was strongly expressed in the
endothelial cells (arrows) of the developing renal vasculature
(A: artery; V: vein). (e) The urothelium of a large developing collecting
duct (arrowhead) and interstitial fibroblast-like cells (arrows)
expressed ADAM19 strongly. (f) Control stainings (Sp6, sense probe)
of normal fetal kidneys were consistently negative. (g) ADAM19 was
strongly expressed in the epithelial cells lining a large cyst (open
arrow) in a patient with multicystic renal dysplasia. Fibroblast-like
cells (arrow) and an occasionally present tubule (arrowhead) in the
fibrotic parenchyma showed strong ADAM19 expression as well. The
cystic lumen is indicated by an *. (h) Control stainings (Sp6, sense
probe) of kidneys with multicystic renal dysplasia were consistently
negative.
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and g). Additionally, immunofluorescence double-stainings
were performed, combining ADAM19 with HB-EGF and
NRG, both possible substrates for ADAM19. ADAM19
almost completely colocalized with NRG in interstitial cells
positive for NRG. The sporadic tubular NRG expression also
showed nearly complete colocalization with ADAM19 (Figure
3a–c). On the other hand, ADAM19 did not colocalize with
tubular or interstitial HB-EGF (Figure 3d–f). Control
sections, in which primary antibodies were replaced by
phosphate-buffered saline (PBS), rabbit immunoglobulins
(Igs), or rabbit anti-alpha 1 inhibitor 3 antibodies, were
negative (Figure 3h).
Associations between the extent of ADAM19 expression and
clinical and pathological parameters
Renal diseases with prominent glomerular mesangial in-
volvement (diabetic nephropathy, FGS, IgA nephropathy, and
systemic lupus nephritis, all classes; n¼ 24) had significantly
higher levels of mesangial ADAM19 than diseases without
prominent mesangial involvement (acute rejection, minimal
change disease, membranous glomerulopathy, Wegener’s
granulomatosis, and MPGN and hypertensive nephropathy;
n¼ 38) (Po0.05) (Figure 4). The association between
increments in glomerular mesangial ADAM19 expression
and aggravated glomerular pathology as indicated by MME
and FGS is shown in Figure 5, providing an assessment of
ADAM19 staining per quartile of MME and FGS, respectively
(Po0.001). The lower mesangial ADAM19 mRNA score in
the fourth quartile of MME and FGS may be related to the
absence of functional cells during advanced stages of
glomerular sclerosis, resulting in lower quantification of
ADAM19. The relation between mesangial ADAM19 and
glomerular influx of macrophages is demonstrated in
Figure 6: increasing levels of mesangial ADAM19 expression
are associated with enhanced influx of macrophages into the
glomerulus (Po0.001). Increasing levels of ADAM19 expres-
Table 3 | Percentage of any positive ADAM19 staining (score 7, +, ++, or +++) in control kidneys and human renal disease
Glomerulus Interstitium Vessels
N
Parietal
epithelium
Visceral
epithelium Endothelium Mes
Proximal
tubules
Distal
tubules Capillaries Endothelium SMC
Control 8 75 100 75 13 0 100 13 100 100
Acute allograft rejection 6 100 83 100 100 100 100 100 100 100
Minimal change disease 6 100 100 100 100 100 100 100 100 100
Membranous
glomerulopathy
5 100 100 100 100 100 100 100 100 100
Wegener’s granulomatosis 5 100 100 100 80 100 100 100 100 100
Hypertensive nephropathy 6 100 100 100 83 100 100 100 100 100
Membranoproliferative
glomerulonephritis
3 100 100 100 100 100 100 100 100 100
Diabetic nephropathy 6 100 100 100 100 100 100 100 100 100
FGS 8 100 100 100 100 100 100 100 100 100
Systemic lupus
erythematosus
5 100 60 100 80 100 100 100 100 100
IgA nephropathy 6 100 83 100 83 67 100 83 100 100
ADAM, a disintegrin and metalloproteinase; FGS, focal glomerulosclerosis; IgA, immunoglobulin A; Mes, mesangium; SMC, smooth muscle cells.
Table 4 | Percentage of very strong ADAM19 staining (score +++) in control kidneys and human renal disease
Glomerulus Interstitium Vessels
N
Parietal
epithelium
Visceral
epithelium Endothelium Mes
Proximal
tubules
Distal
tubules Capillaries Endothelium SMC
Control 8 0 0 0 0 0 13 0 13 0
Acute allograft rejection 6 0 0 17 0 0 83 0 13 17
Minimal change disease 6 80 60 0 0 0 100 0 33 17
Membranous
glomerulopathy
5 67 0 67 0 0 100 17 100 80
Wegener’s granulomatosis 5 20 0 40 0 0 80 0 25 25
Hypertensive nephropathy 6 50 17 50 0 0 100 0 67 50
Membranoproliferative
glomerulonephritis
3 67 67 33 0 67 67 33 100 67
Diabetic nephropathy 6 17 17 33 0 0 100 0 83 17
FGS 8 29 13 13 0 0 71 13 17 0
Systemic lupus
erythematosus
5 40 0 20 20 0 80 0 20 40
IgA nephropathy 6 17 17 17 0 0 100 0 0 0
ADAM, a disintegrin and metalloproteinase; FGS, focal glomerular sclerosis; IgA, immunoglobulin A; Mes, mesangium; SMC, smooth muscle cells.
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sion in peritubular capillaries and in proximal tubules are
significantly associated with more extensive interstitial
fibrosis (Po0.05) (Figures 7 and 8). Loss of peritubular
capillaries, common during advanced stages of interstitial
fibrosis, could explain the slightly lower score of peritubular
ADAM19 in the highest interstitial fibrosis group (Figure 7).
The association between proximal tubular ADAM19 and
renal function, as measured by serum creatinine, is demon-
strated in Figure 9 (Po0.05).
DISCUSSION
The present study was designed to investigate the distribution
of the metalloproteinase ADAM19 in human nephrogenesis
and renal disease and to relate the latter findings to the
severity of renal disease as measured by clinical and
pathological parameters. We observed widespread ADAM19
expression during nephrogenesis, suggesting developmental
regulation. In renal disease, ADAM19 is markedly upregu-
lated or de novo expressed in various renal cell types when
compared to normal human kidneys. Moreover, ADAM19
showed colocalization with NRG, both at interstitial and
tubular level. Increasing glomerular mesangial ADAM19
expression is associated with glomerular fibrosis and
inflammation. Increments in peritubular endothelial and
proximal tubular ADAM19 are associated with interstitial
fibrosis. Together with the observed association that renal
function declines when tubular ADAM19 increases, these
data suggest that ADAM19 is an important mediator in renal
pathophysiology.
The abundant expression of ADAM19 in human nephro-
genesis points to an important role in development.
ADAM19’s presence in developing renal structures may well
be explained by its functioning in shedding of growth factors
from the cell membrane. One group of growth factors is of
special interest: the EGF family, whose members are ligands
for the ErbB family of receptor tyrosine kinases. ADAM19 is
known to cleave HB-EGF.11 Conflicting data exist on the role
of ADAM19 in shedding of another EGF-like growth factor
family member, NRG. Shirakabe et al.18 demonstrated the
proteolytic processing of b-type NRGs by ADAM19. How-
ever, in another report, this particular sheddase activity was
not found.11 Studies in mice with targeted HB-EGF and NRG
gene mutations revealed abnormalities in nervous system and
heart development.19–22 Analysis of the kidney was precluded
because these mice died midway through embryogenesis.
NRGs are abundantly expressed in mouse embryonic
kidneys, with a peak at day 11 being the crucial develop-
mental stage of urogenital organs.23 In normal human fetal
kidneys, c-ErbB2 (HER2), through which NRGs via ErbB3
(HER3) and ErbB4 (HER4) achieve their downstream
signaling, is found in tubular structures, similar to EGF
receptor expression, through which HB-EGF exerts its
activity.24 ADAM19 colocalized with NRG mainly in inter-
stitial fibrotic areas, but also at the basolateral surface of the
tubules, whereas no ADAM19-HB-EGF co-expression was
identified. These data support the possibility of an active
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Figure 2 | ADAM19 mRNA expression in the normal human
kidney and in renal disease. All photographs are from representa-
tive biopsies of the disease groups. Original magnification  400,
unless stated otherwise (a: original magnification  200, and b) In
the normal human kidney, ADAM19 mRNA was moderately
expressed in the distal tubular epithelial cells (arrows), whereas the
proximal tubules were negative (arrowhead). (b) The glomeruli
showed moderate staining in a few visceral epithelial cells (open
arrows). (c) The endothelial cells (arrows) and vascular smooth muscle
cells (arrowheads) of the renal vasculature stained, respectively,
moderately and weakly positive for ADAM19 (A: artery; V: vein)
(original magnification  200). (d) Control stainings (Sp6, sense
probe) of normal human kidneys were consistently negative (original
magnification  200). (e) In MPGN, the epithelial cells of damaged,
dilated tubules (arrows), and detached tubular cells (arrowheads)
showed massive ADAM19 expression. (f) In diabetic nephropathy,
strong ADAM19 expression was observed in the glomerular parietal
epithelium (arrowheads) and in the mesangial area forming a
Kimmelstiel–Wilson lesion (arrows). (f) De novo expression of ADAM19
mRNA in proximal tubules was observed (open arrows) (g). In
endothelial cells (arrow) and vascular smooth muscle cells (arrow-
head) of the renal vasculature in hypertensive nephropathy,
respectively, massive and moderate ADAM19 mRNA expression was
observed. (h) Control stainings (Sp6, sense probe) of renal disease
were consistently negative.
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ADAM19-NRG pathway in renal disease and shed new light
on the role of ADAM19 in the renal shedding of EGF-like
growth factors.
In ADAM19 knockout mice, several cardiac defects are
noted, among others disrupted smooth muscle cell ensheath-
ment of blood vessels.14,15 The baseline ADAM19 expression
in vascular smooth muscle cells points to a role in
maintaining the integrity of vascular smooth muscle cell
ensheathment. Moreover, in various renal diseases, we noted
marked vascular intima thickening. Cells in these lesions are
thought to be derived from medial smooth muscle cells.
Strikingly, these deranged cells had less ADAM19 expression
as compared with medial smooth muscle cells, supporting the
suggested role in ensheathment.
Interestingly, tubular, endothelial, and mesangial
ADAM19 expression was downregulated in the normal adult
kidney when compared with the fetal or the young adult
kidney, and again upregulated in renal disease. This
reactivation of developmental pathways supports the possible
role for ADAM19 in growth-promoting activities in the
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TRITC - ADAM19 Control -unrelated antibody
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Figure 3 | Immunofluorescence double-stainings for ADAM19 with HB-EGF and NRG. All photographs are from representative areas of an
acute rejection biopsy. Original magnification  200, unless stated otherwise. (g) In tubular epithelial cells, ADAM19 was predominantly
expressed in the central cytoplasm (thick arrows). Furthermore, ADAM19 expression was noted at the basolateral side (arrows) and also, to a
lesser degree, at the luminal side (arrowhead). (g: enlargement of a, original magnification  640). (a) Broadened, fibrotic, interstitial areas
(thick arrows) showed ADAM19 expression as well. (b) NRG was mainly expressed in fibrotic, interstitial areas (thick arrows), and sporadically
in the tubular epithelium (arrows). (c) Double-positive areas are shown in the overlay picture: ADAM19 colocalized with NRG in both the
tubular epithelium (arrows) and interstitial fibrotic areas, (thick arrows). (e) HB-EGF expression was hardly observed in tubular structures,
whereas most interstitial fibrotic areas showed positive HB-EGF staining. (f) No double-positive ADAM19-HB-EGF areas were identified in
the overlay picture. (h) Control stainings with an unrelated rabbit anti-alpha 1 inhibitor 3 antibody were negative.
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development of fibrotic lesions in renal disease. Furthermore,
in renal disease, mesangial expression of ADAM19 was
related to glomerular macrophage influx and development of
glomerular fibrosis. Fritsche et al.16 suggested that short-term
ADAM19 expression by monocytes is important for the early
adhesion and migration process of monocytes during
extravasation. As macrophages are the principle inducer of
mesangial differentiation and activation, upregulation of
mesangial ADAM19 might well be part of that macrophage-
attractant process. Family member ADAM15, with respect to
its domain structures closely related to ADAM19, is involved
in mesangial cell migration.25 Together with the high
expression of ADAM19 in mesangial areas of diseases with
prominent mesangial involvement, this suggests a specific
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Figure 4 | Mesangial ADAM19 expression in mesangial diseases
versus non-mesangial diseases. Mesangial ADAM19 mRNA
expression (mean7s.d.) is significantly higher in diseases with
mesangial involvement (diabetic nephropathy, focal glomerular
sclerosis, IgA nephropathy, and systemic lupus erythematosus, all
classes) than diseases without mesangial involvement (acute allograft
rejection, minimal change disease, membranous glomerulopathy,
Wegener’s granulomatosis, hypertensive nephropathy, and MPGN).
(Mann–Whithney U-test, Po0.05).
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Figure 5 | Mesangial ADAM19 expression is associated with
glomerular damage. Mesangial ADAM19 expression is associated
with (a) MME and (b) FGS. A significant difference in mesangial
ADAM19 mRNA expression (mean7s.d.) is present between
(a) quartiles of MME and (b) FGS (Kruskall–Wallis, Po0.001).
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Figure 6 | Mesangial ADAM19 expression is associated with
glomerular macrophage influx. A significant difference in
mesangial ADAM19 mRNA expression (mean7s.d.) is present
between the quartiles of glomerular macrophages (Kruskall–Wallis,
Po0.001).
0 1 4
0
1
2
3
4 P < 0.05
AD
AM
19
 in
 p
er
itu
bu
la
r
ca
pi
lla
rie
s
Interstitial fibrosis, scores 0–4
32
Figure 7 | Peritubular capillary ADAM19 expression is associated
with interstitial fibrosis. A significant difference in peritubular
capillary ADAM19 mRNA expression (mean7s.d.) is present between
the scores of interstitial fibrosis (scores 0–4) (Kruskall–Wallis, Po0.05).
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Figure 8 | Proximal tubular ADAM19 expression is associated
with interstitial fibrosis. A significant difference in proximal tubular
ADAM19 mRNA expression (mean7s.d.) is present between the
scores of interstitial fibrosis (scores 0–4). (Kruskall–Wallis, Po0.05).
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Figure 9 | Proximal tubular ADAM19 expression is associated
with serum creatinine. A significant difference in proximal tubular
ADAM19 mRNA expression (mean7s.d.) is present between the
quartiles of serum creatinine (Kruskall–Wallis, Po0.05).
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role for ADAM19 in mesangial proliferative processes.
Another route of action in the development of glomerular
pathology could be executed through ADAM19’s disintegrin
and metalloproteinase domain in remodeling extracellular
matrix. The metalloproteinase domain of ADAM19 possesses
proteolytic activity26 and a function in extracellular matrix
remodeling for ADAM19 has recently been suggested in
pregnancy: high levels of ADAM19 were found in placental
cells on days 18 and 26 of pregnancy, a critical period for
implantation.8
In addition to associations of ADAM19 with glomerular
pathology, we noted an intriguing relation between inter-
stitial fibrosis and ADAM19 expression in proximal tubules
and peritubular capillaries. Proximal tubular cells are
involved in the development and progression of interstitial
fibrosis by stimulating cortical fibroblast proliferation and
collagen synthesis.27 These (pro)fibrotic events could be
supported by ADAM19 through its role in protein ecto-
domain shedding and extracellular matrix remodeling. As
associations between interstitial fibrosis and presence of
monocytes are frequently described, a role for peritubular
ADAM19 in the development of interstitial damage could be
explained by ADAM19’s presumed function in the migration
of monocytes into the tissue.16
In conclusion, based on the widespread expression during
human nephrogenesis, a role for ADAM19 in growth
promotion and regulation is likely. In combination with the
observed associations between ADAM19 and glomerular and
interstitial damage, the high ADAM19 expression in renal
disease may be involved in profibrotic and proinflammatory
processes that ultimately lead to renal deterioration. Further
studies assessing functional activities of ADAM19 in cell
systems, experimental models, and human renal disease are
needed.
MATERIALS AND METHODS
Patients and tissue processing
We collected renal biopsies from 56 patients who were examined in
the University Medical Center Groningen, The Netherlands. Patients
were diagnosed by a nephropathologist unrelated to this study and
the following disease groups were included: minimal change disease
(n¼ 6), membranous glomerulopathy (n¼ 5), Wegener’s granulo-
matosis (n¼ 5), hypertensive nephropathy (n¼ 6), diabetic nephro-
pathy (n¼ 6), MPGN (n¼ 3), focal glomerular sclerosis (n¼ 8),
systemic lupus erythematosus (class II, n¼ 3; class III, n¼ 1; class
IV, n¼ 1), IgA nephropathy (n¼ 6), and acute allograft rejection
(n¼ 6). Control tissue (n¼ 8) was obtained from the unaffected
parts of kidneys from patients with renal carcinoma. Patient
characteristics and clinical parameters were collected for all different
groups. Tissue was fixed in 4% paraformaldehyde and processed for
paraffin embedding. All procedures and use of anonymized tissue
were performed according to national ethical guidelines.
Fetal tissue
Kidneys from human fetuses (12–41 weeks of gestation) (n¼ 17),
from infants (7 and 18 months) (n¼ 2), from patients with
multicystic renal dysplasia (n¼ 2), and nephroblastomatosis (n¼ 1)
were collected from the paraffin archive of our department. Normal
kidney tissue was obtained from fetuses that died of placental
pathology and had no congenital abnormalities. Five fetal kidneys
were excluded owing to maceration. Kidney tissue was obtained
from two infants that died of circulatory failure and had no
congenital abnormalities. Different stages of renal development were
determined by a paediatric pathologist. All procedures and use of
anonymized fetal tissue were performed according to national
ethical guidelines.
Assessment of renal morphological damage
Renal biopsies, stained with hematoxylin eosin, methanamine-silver,
or periodic acid-Schiff, were blindly scored for glomerular MME,
FGS, and interstitial fibrosis. MME was scored positive when
broadening of mesangial areas was 2–3 times that of the mesangial
width seen in glomeruli of control renal tissue. FGS was scored
positive when collapse of capillary lumina, MME, hyalinosis, and
adhesion of the glomerular tuft to Bowman’s capsule were
simultaneously present. Glomeruli were scored for MME and FGS:
unaffected glomeruli were scored as 0, if one glomerular quadrant
was affected a score of 1 was given, two quadrants affected was
scored as 2, three quadrants affected as 3, and all quadrants affected
as 4. The means for MME and FGS of all scored glomeruli of 1
biopsy were calculated. Interstitial fibrosis was scored positive when
tubular atrophy and broadening of the peritubular compartment
were simultaneously present. Scores of 0–4 were assigned: a score of
0 indicated no interstitial fibrosis, a score of 1 indicated 0–25%
involvement of the total interstitial surface of the biopsy, a score of 2
25–50% involvement, a score of 3 50–75% involvement, and a score
of 4 75–100% involvement. Glomerular macrophages, as assessment
of inflammation, were manually counted. Biopsies were routinely
stained with CD68-antibody (Dako-Cytomation, Glostrup, Den-
mark). All glomeruli in each biopsy were evaluated and the mean
glomerular macrophage number per biopsy was calculated. Median
and range of MME, FGS, interstitial fibrosis, and glomerular
macrophages were determined for all disease groups, using the mean
scores of the individual biopsies.
RNA in situ hybridization
ADAM19-FR polymerase chain reaction product of 507 bp was
subcloned in pCRII-TOPO vector (Invitrogen, Carlsbad, CA, USA).
Insert lengths were routinely checked by amplification with M13
forward and M13 reverse primers, and restriction enzyme analysis
with EcoR1. Orientation of the polymerase chain reaction product
was determined by polymerase chain reaction using ADAM19-
specific primers in combination with vector-specific M13F and
M13R primers. This was confirmed by sequence analysis of the
ADAM19 construct. Deparaffinized sections were air-dried, treated
with Triton X-100, followed by proteinase K (5mg/ml in tris-
buffered saline) (Roche, Mannheim, Germany) at 371C for 20 min,
washed with PBS, and incubated with 10 ng/100 ml digoxin-labeled
probe (antisense or sense) in a hybridization solution consisting of
100 ml 50Denhardt’s solution, 1 ml 20 standard sodium citrate,
1 ml 50% dextran sulfate, 2.5 ml formamide, 200 ml (25 mg/ml)
t-RNA, 49 ml 1 M dithiothreitol, and 125 ml (10 mg/ml) salmon
sperm DNA overnight at 551C. After washing, slides were treated
with 2 U/ml RNase T1 (Sigma-Aldrich, Steinheim, Germany) in
1 mM ethylenediaminetetraacetic acid (pH 8.0) and 2 standard
sodium citrate at 371C for 30 min Positive cells were visualized with
anti-digoxin-labeled alkaline phosphatase (Roche) for 1 h at 371C in
0.1 M maleic acid buffer containing 0.15 M NaCl, 1% blocking buffer,
and 2% normal sheep serum. Staining reaction was performed for
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1 h at 371C with nitroblue tetrazolium chloride and 5-bromo-4-
chloro-30-indolyphosphate p-toluidine salt (Roche) in 1 ml acid-fast
buffer (pH¼ 9.0) containing 50 mM MgCl2 and 0.01 M levamisole.
Immunofluorescence staining
To detect ADAM19 and NRG colocalization, frozen sections (3mm)
were fixed in acetone for 10 min and incubated with a mouse anti-
human NRG monoclonal antibody (1:10, dilution in PBS/1%
bovine serum albumin; Acris, Germany) for 1 h. Binding of the
antibody was detected by sequential incubations of 30 min. with
goat anti-mouse-fluorescein isothiocyanate antibody (1:25; Dako)
and donkey anti-goat-fluorescein isothiocyanate antibody (1:50).
Antibodies were diluted in PBS, supplemented with 1% normal
human serum. Next, slides were incubated with 5% normal goat
serum (Sigma-Aldrich) for 30 min. Then, ADAM19 was detected
using a rabbit anti-human ADAM19 polyclonal antibody (1:50,
dilution in PBS/1% bovine serum albumin; Biogenesis, UK) after
incubation for 60 min, followed by goat anti-rabbit-tetramethyl
rhodamine isothiocyanate antibody (1:25, diluted in PBS; Dako) for
30 min. To colocalize ADAM19 and HB-EGF, frozen sections were
incubated with a goat anti-human HB-EGF polyclonal antibody
(1:50, dilution in PBS/1% bovine serum albumin; R&D systems,
USA) for 1 h. Binding of the antibody was detected by donkey anti-
goat-fluorescein isothiocyanate antibody for 30 min (1:100, diluted
in PBS with 1% normal human serum). Next, slides were incubated
with 5% normal goat serum (Sigma-Aldrich) for 30 min. Then,
ADAM19 was detected using a rabbit anti-human ADAM19
polyclonal antibody (1:50, dilution in PBS/1% bovine serum
albumin; Biogenesis) after incubation for 60 min, followed by goat
anti-rabbit-tetramethyl rhodamine isothiocyanate (1:25, diluted in
PBS; Dako) for 30 min. Single ADAM19 immunofluorescence
staining was performed as described above, without steps for
NRG/HB-EGF staining. Nuclei were stained with DAPI and sections
mounted with citifluor (Agar scientific, UK). After incubation with
the fluorescent-labeled antibodies, slides were kept in the dark until
studied. To determine the specificity of the ADAM19 antibody, we
performed two types of control tests. First, kidney sections were
incubated with unrelated rabbit anti-alpha 1 inhibitor 3 antibody or
with rabbit Igs. Second, sections were incubated with PBS without
the primary antibodies. Fluorescence microscopy was performed
using a Leica DMLB microscope (Leica Microsystems, The Nether-
lands), Leica DC300F camera, and Leica QWin 2.8 software.
Scoring of ADAM19 mRNA expression
In control kidneys and renal disease, ADAM19 mRNA localization
and staining intensity in various glomerular, interstitial, and
vascular structures were scored semiquantitatively on a scale of 0
to þ þ þ : 0 (no staining), 7(weak staining), þ (moderate
staining), þ þ (strong staining), and þ þ þ (very strong
staining). To report a score for the disease group as a whole, these
data were converted into percentages as described previously.28,29
Briefly, we compared the semiquantitative scores for a specific renal
structure of all biopsies within one disease group. For example, six
patients with hypertensive nephropathy were analyzed. Three
patients scored þ þ (strong) and three scored þ þ þ (very
strong) in the parietal epithelium. After conversion of these
semiquantitative data into percentages, 100% of the hypertensive
nephropathies scored strong staining (six out of six scored at least
þ þ ) in the parietal epithelium and 50% scored very strong staining
(three out of six scored þ þ þ ). In Tables 3 and 4, the percentages
of ADAM19 staining intensity in all disease groups are presented for
any positive staining (defined as7, þ , þ þ , or þ þ þ ) and very
strong staining (defined as þ þ þ ). The ADAM19 staining
intensity in various developing renal structures of human fetal
kidneys was evaluated in the same manner as for control kidneys
and renal disease.
Statistical analysis
The Mann–Whitney U-test was used to detect differences in clinical
and pathological parameters between controls and disease groups.
To detect associations between MME, FGS, or glomerular macro-
phage influx and ADAM19 expression, these factors were split into
quartiles, as described previously.28 The first quartile represents
biopsies with the lowest MME, FGS, or glomerular macrophages
and the fourth quartile represents the highest scores. For interstitial
fibrosis, the absolute score (0–4) was used as a break-up to study for
possible associations with ADAM19. Kruskal–Wallis test was used to
detect differences between the break-up groups. P-values of o0.05
were considered significant.
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